IOVA

#1540
Iovance Biotherapeutics, Inc. - Common Stock
8.4 6 USD
+0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
8.30
8.69
Intervallo Annuale
1.76
9.36
Variazione giornaliera
+2.17%
Variazione Mensile
+106.34%
Variazione di 6 mesi
+133.70%
Variazione Annuale
+288.07%
Chiusura Precedente
8.2 8
Open
8.3 1
Minimo
8.3 0
Massimo
8.6 9
Volume
2 150
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
IOVANCE BIOTHERAPEUTICS, INC. current report, Q1 FY2026
8-K

IOVANCE BIOTHERAPEUTICS, INC. current report, Q2 FY2023

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by IOVANCE BIOTHERAPEUTICS, INC. on June 6, 2023. The meeting was conducted virtually via live webcast. Approximately 85.051% of all outstanding common stock (190,819,338 shares) was present either in person or by proxy.

Key Financial Metrics

This filing is a Current Report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the company's most recent 10-K or 10-Q filings for financial metrics.

Material Changes and Voting Results

Stockholders voted on six proposals, all of which were approved or resulted in the re-election of nominees. Key outcomes include:

  • Board Composition: Seven directors were re-elected. Notably, Wendy Dixon, Ph.D., did not stand for re-election as previously announced; her departure was not due to any disagreement with the Company.
  • Executive Compensation: The non-binding advisory proposal to approve named executive officer compensation was approved.
  • Equity Plans:
    • The 2018 Equity Incentive Plan share reserve was increased from 20,700,000 to 29,700,000 shares.
    • The 2020 Employee Stock Purchase Plan share reserve was increased from 500,000 to 1,400,000 shares.
  • Authorized Capital: The number of authorized common shares was increased from 300,000,000 to 500,000,000 shares.
  • Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.

Guidance, Outlook, and Risks

This filing does not provide updated financial guidance, operational outlook, or new risk factors. The document notes that the decision regarding Dr. Dixon's departure from the Board was not related to any disagreement on operations, policies, or practices.

Investor Verification Checklist

  • Verify the impact of the increased share authorization (to 500 million) on potential future dilution.
  • Review the specific terms of the amended 2018 Equity Incentive Plan and 2020 Employee Stock Purchase Plan to understand the new grant limits.
  • Confirm the composition of the new Board of Directors and the timeline for filling the vacancy left by Dr. Dixon.
  • Check the most recent 10-Q or 10-K for financial health metrics, as this 8-K contains no financial data.

Notizie